**Table S1.** Baseline characteristics, clinical course of index hospitalization and pharmacotherapy in hospitalized HFmrEF patients in SR stratified by heart rate at discharge <70 and ≥70 b.p.m. (from the Polish cohort of the ESC-HF-LT registry).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HFmrEF,**  **SR <70/min**  ***(n=21; 46.7*%)** | **HFmrEF,**  **SR ≥70/min**  ***(n=24; 53.3*%)** | ***P*-value** |
| **Demographics** | | | |
| Age, yrs | 69.8 (63.7-76.7) | 70.9 (58.0-79.0) | 0.84 |
| Male | 15 (71.4%) | 20 (83.3%) | 0.48 |
| BMI, kg/m2 | 28.4 (25.5-30.7) | 30.3 (25.2-31.4) | 0.86 |
| **Medical history** | | | |
| Previous HF hospitalization | 11 (52.4%) | 11 (45.8%) | 0.77 |
| Ischemic etiology | 17 (81.0%) | 18 (75.0%) | 0.73 |
| Valve disease | 2 (9.5%) | 3 (12.5%) | 1.00 |
| Dilated cardiomyopathy | 0 (0.0%) | 1 (4.2%) | 1.00 |
| Hypertension | 16 (76.2%) | 19 (79.2%) | 1.00 |
| Atrial fibrillation | 3 (14.3%) | 6 (25.0%) | 0.47 |
| Coronary artery disease | 11 (52.4%) | 17 (70.8%) | 0.23 |
| Prior PCI or CABG | 9 (42.9%) | 9 (37.5%) | 0.77 |
| Peripheral artery disease | 3 (14.3%) | 2 (8.3%) | 0.65 |
| Diabetes | 8 (38.1%) | 7 (29.2%) | 0.55 |
| Chronic kidney disease | 4 (19.0%) | 3 (12.5%) | 0.69 |
| COPD | 0 (0.0%) | 5/23 (21.7%) | 0.05 |
| Stroke | 1 (4.8%) | 1 (4.2%) | 1.00 |
| Current smoking | 16 (76.2%) | 15 (62.5%) | 0.36 |
| Alcohol\* | 14 (66.7%) | 16/23 (69.6%) | 1.00 |
| **Clinical status at admission** | | | |
| NYHA class | | | 0.12 |
| I | 0/20 (0%) | 0 (0%) | - |
| II | 12/20 (60%) | 7 (29.2%) | **-** |
| III | 6/20 (30%) | 10 (41.7%) | **-** |
| IV | 2/20 (10%) | 7 (29.2%) | **-** |
| Heart rate, b.p.m. | 75.0 (64.0-85.0) | 76.0 (72.0-90.0) | 0.28 |
| SBP, mmHg | 140.0 (110.0-150.0) | 121.5 (110.0-140.0) | 0.34 |
| DBP, mmHg | 80.0 (70.0- 90.0) | 72.5 (60.0-80.2) | 0.39 |
| **Laboratory findings at admission** | | | |
| Hemoglobin, g/dl | 13.6 (12.7-14.2) | 12.9 (12.0-14.3) | 0.48 |
| Serum creatinine, mg/dl | 1.0 (0.9-1.3) | 1.1 (0.8-1.4) | 0.90 |
| Serum sodium, mmol/l | 141.0 (139.0-142.6) | 140.5 (138.0-141.2) | 0.29 |
| Serum potassium, mmol/l | 4.4 (4.2-4.9) | 4.4 (4.1-4.6) | 0.27 |
| BNP, pg/ml | -  *1* | -  *2* | - |
| NT-proBNP, pg/ml | 1287.0 (1132.5-2475.5)  *7* | 1591.0 (844.0-7525.0)  *9* | 0.79 |
| **Clinical status at discharge** | | | |
| NYHA class | | | 0.79 |
| I | 0 (0.0) | 2 (8.3%) | **-** |
| II | 21 (100.0) | 17 (70.8%) | **-** |
| III | 0 (0.0) | 4 (16.7%) | **-** |
| IV | 0 (0.0) | 1 (4.2%) | **-** |
| Heart rate, b.p.m. | 60.0 (57.0-66.0) | 77.0 (73.5-80.0) | **<0.001** |
| Change in heart rate, b.p.m.\*\* | -14.0 (-25.0 to -1.0) | 0.0 (-7.0 to 3.0) | **0.015** |
| SBP, mmHg | 120.0 (115.0-130.0) | 115.0 (102.2-121.2) | 0.13 |
| DBP, mmHg | 70.0 (60.0-80.0)  *20* | 70.0 (65.0-70.0) | 0.97 |
| **Laboratory findings at discharge** | | | |
| Hemoglobin, g/dl | 13.0 (10.6-14.3)  *11* | 12.4 (11.7-13.8)  *16* | 0.92 |
| Serum creatinine, mg/dl | 1.0 (0.9-1.2)  *14* | 1.0 (0.9-1.2)  *15* | 0.84 |
| Serum sodium, mmol/l | 141.2 (140.1-142.9)  *14* | 140.4 (138.7-141.3)  *16* | 0.12 |
| Serum potassium, mmol/l | 4.5 (4.2-4.7)  *15* | 4.4 (4.3-4.6)  *16* | 0.72 |
| **Pharmacotherapy at hospital discharge** | | | |
| Beta-blocker | 20 (95.2%) | 21 (87.5%) | 0.61 |
| Dose of beta-blocker \*\*\* | 5.0 (2.5-5.0)  *21* | 3.8 (2.5-8.1)  *20* | 0.96 |
| Digoxin | 1 (4.8%) | 1 (4.2%) | 1.00 |
| Ivabradine | 0 (0%) | 0 (0%) | 1.00 |
| Amiodaron | 4 (19.0%) | 1 (4.2%) | 0.17 |
| Other antiarrhythmics | 1 (4.8%) | 4 (16.7%) | 0.35 |
| Diuretics | 14 (66.7%) | 17 (70.8%) | 1.00 |
| ACE-I\*\*\*\* | 21 (100.0%)  *21* | 20 (83.3%)  *24* | 0.11 |
| Dose of ACE-I | 5.0 (2.5 to 10.0)  *21* | 5.0 (2.5 to 10.0)  *20* | 0.86 |
| ARB | 0 (0.0%) | 3 (12.5%) | 0.24 |
| Aldosterone antagonist | 12 (57.1%) | 18 (75.0%) | 0.23 |
| Dose of aldosterone antagonist\*\*\*\*\* | -  *0* | -  *3* | - |
| CCB | 6 (28.6%) | 5 (20.8%) | 0.73 |
| Statins | 20 (95.2%) | 18 (75.0%) | 0.10 |
| Anticoagulants | 6 (28.6%) | 7 (29.2%) | 1.00 |
| Antiplatelets | 17 (81.0%) | 19 (79.2%) | 1.00 |

ACE-I - angiotensin-converting-enzyme inhibitor, ARB - angiotensin receptor blocker, BNP - B-type natriuretic peptide, BMI - body mass index, b. p. m. - beats per minute, CABG - coronary artery bypass grafting, CCB – calcium channel blocker, COPD - chronic obstructive pulmonary disease, DBP – diastolic blood pressure, ESC-HF-LT - European Society of Cardiology Heart Failure Long-Term Registry, HF - heart failure, HFmrEF – heart failure with mid-range ejection fraction, NT-proBNP - N-terminal-pro- B-type natriuretic peptide, NYHA – New York Heart Association, PCI - percutaneous coronary intervention, SBP - systolic blood pressure, SR – sinus rhythm, yrs – years

Red bolded text indicates *p-*values <0.05.

Numbers in italics indicate available cases for the analyzed continuous variable.

\* former or sometimes

\*\* change was calculated as the heart rate on admission minus the heart rate at discharge

\*\*\* total daily doses of commonly used beta-blockers converted to the corresponding dose of bisoprolol

\*\*\*\* total daily doses of commonly used ACE-Is converted to the corresponding dose of ramipril

\*\*\*\*\* total daily doses of commonly used aldosterone antagonists converted to the corresponding dose of eplerenone